Cost-effectiveness of the oral adsorbent AST-120 versus placebo for chronic kidney disease

Nephrology

Volumn 13, Issue 5, 2008, Pages 419-427

  Takahashi, Tomohiko ^a,b   Reed, Shelby D ^a   Schulman, Kevin A ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b KUREHA CORPORATION   (Japan)

Author keywords

AST 120; Chronic kidney failure; Cost benefit analysis; Japan

Indexed keywords

AST 120; CREATININE; PLACEBO;

ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DEATH; DISEASE COURSE; FEMALE; GROWTH RATE; HEALTH CARE COST; HEALTH STATUS; HEMODIALYSIS; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS;

ADMINISTRATION, ORAL; ADSORPTION; ADULT; CARBON; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; FEMALE; HEALTH CARE COSTS; HUMANS; JAPAN; KIDNEY FAILURE, CHRONIC; MALE; MARKOV CHAINS; MIDDLE AGED; OXIDES; QUALITY-ADJUSTED LIFE YEARS; RENAL AGENTS;

EID: 49549108917     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2008.00960.x     Document Type: Article

References (37)

1. Nakai S, Wada A, Kitaoka T et al. An overview of regular dialysis treatment in Japan (as of December 31, 2004). Ther. Apher. Dial. 2006 10 : 476 91.
2. United States Renal Data System. 2004 USRDS Annual Data Report Atlas Cited 29 October 2007.] Available from URL http://www.usrds.org/atlas.htm
3. Ministry of Health, Labor and Welfare. National Medical Care Expenditure 2002 (in Japanese). Tokyo : Health and Welfare Statistics, 2004 Cited 29 October 2007.] Available from URL: http://www.mhlw.go.jp/toukei/saikin/hw/k-iryohi/05/ dl/data.pdf.
4. Jafar TH, Schmid CH, Landa M et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann. Intern. Med. 2001 135 : 73 87.
5. Wright JT Jr., Bakris G, Greene T et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 2002 288 : 2421 32.
6. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet 2003 361 : 117 24.
7. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 2001 345 : 851 60.
8. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 2001 345 : 861 9.
9. National Kidney Foundation. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney diseases. Am. J. Kidney Dis. 2004 43 (Suppl 1 S1 268.
10. Hogan TJ, Elliott WJ, Seto AH, Bakris GL. Antihypertensive treatment with and without Benazepril in patients with chronic renal insufficiency. Pharmacoeconomics 2002 20 : 37 47.
11. Van Hout BA, Simeon GP, McDonnell J, Mann JF. Economic evaluation of benazepril in chronic renal insufficiency. Kidney Int. 1997 52 (Suppl 63 S159 62.
12. Aoyama I, Shimokata K, Niwa T. Combination therapy with benazepril and oral adsorbent ameliorates progressive renal fibrosis in uremic rats. Nephron. 2002 90 : 297 312.
13. Miyazaki T, Aoyama I, Ise M, Seo H, Niwa T. An oral sorbent reduces overload of indoxyl sulphate and gene expression of TGF-β1 in uraemic rat kidneys. Nephrol. Dial. Transplant. 2000 15 : 1773 81.
14. Koide K, Koshikawa S, Yamane Y et al. Clinical evaluation of AST-120 in the treatment of chronic renal failure. Multi-center, double-blind study in comparison with placebo [in Japanese Clin. Eval. 1987 15 : 487 525.
15. Koide K, Koshikawa S, Yamane Y et al. Clinical evaluation of AST-120 on suppression of progression of chronic renal failure. Multi-center, double-blind study in comparison with placebo [in Japanese Clin. Eval. 1987 15 : 527 64.
16. Takahashi N, Kawaguchi T, Suzuki T. Therapeutic effects of long-term administration of an oral adsorbent in patients with chronic renal failure: Two-year study. Int. J. Urol. 2005 12 : 7 11.
17. Kang HY, Cho W, Lee S, Kim HJ, Lee HY, Woo TW. Estimating the cost savings due to the effect of Kremezin in delaying the initiation of dialysis treatments among patients with chronic renal failure [in Korean J. Prev. Med. Pub. Health 2006 39 : 149 58.
18. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am. J. Kidney Dis. 2002 39 (Suppl 1 S46 75.
19. Mitch WE, Walser M, Buffington GA, Lemann J Jr. A simple method of estimating progression of chronic renal failure. Lancet 1976 18 : 1326 8.
20. Diagnosis Procedure Combination (DPC). Handbook 10: Urology and the Male Genitalia in Japanese Tokyo : Shakai-hoken Kenkyujyo, 2006.
21. Japanese Ministry of Health, Labour and Welfare. Revised Point Fee System for Social Insurance, 2006 in Japanese Tokyo : Shakai-hoken Kenkyujyo, 2006.
22. Hidai H. Need for an incentive-based reimbursement policy toward quality care for dialysis patient management. Kidney Int. 2000 58 : 363 73.
23. Tu F, Anan M, Kiyohara Y, Okada Y, Nobutomo K. Analysis of hospital charges for ischemic stroke in Fukuoka. Japan Health Policy 2003 66 : 239 46.
24. Takahashi S. Research on DRG/PPS in the field of nephrology in Japanese Hosp. Adm. 2001 38 : 161 9.
25. Japanese Ministry of Health, Labour and Welfare. Standard Prices for Medicines in 2006 in Japanese Tokyo : Shakai-hoken Kenkyujyo, 2006.
26. Statistics Bureau, Japanese Ministry of Internal Affairs and Communications. Consumer price index in Japan in Japanese]. [Cited 29 October 2007.] Available from URL: http://www.stat.go.jp/data/cpi/
27. Smith DG, Nguyen AB, Peak CN, Frech FH. Markov modeling analysis of health and economic outcomes of therapy with valsartan versus amlodipine in patients with type 2 diabetes and microalbuminuria. J. Manag. Care. Pharm. 2004 10 : 26 32.
28. Flowers CR, Veenstra D. The role of cost-effectiveness analysis in the era of pharmacogenomics. Pharmacoeconomics 2004 22 : 481 93.
29. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000 17 : 479 500.
30. Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Cordonnier DJ. An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: Cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings. Nephrol. Dial. Transplant. 2003 18 : 2059 66.
31. Rodby RA, Chiou C, Borenstein J et al. The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy. Clin. Ther. 2003 25 : 2102 18.
32. Marier J, Lee J, Kambhampati S et al. Effects of repeated oral adsorbent AST-120 on serum creatinine and other markers of renal function. Am. J. Nephrol. 2006 26 : 136 41.
33. Shoji T, Wada A, Inoue K et al. Prospective randomized study evaluating the efficacy of the spherical adsorptive carbon AST-120 in chronic kidney disease patients with moderate decrease in renal function. Nephron. Clin. Pract. 2007 105 : c99 107.
34. Sanaka T, Akizawa T, Koide K, Koshikawa S. Clinical analysis of renoprotective responding patients administrated with oral adsorbent in chronic renal failure secondary to chronic glomerulonephritis. Ther. Apher. Dial. 2003 7 : 269 78.
35. Schulman G, Agarwal R, Acharya M, Berl T, Blumenthal S, Kopyt N. A multicenter, randomised, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. Am. J. Kidney Dis. 2006 47 : 565 77.
36. A phase III, randomized, double-blind, placebo-controlled study of AST-120 for evaluating prevention of progression in chronic kidney disease (EPPIC-1) Cited 30 October 2007.] Available from URL: http://www.clinicaltrial. gov/ct/show/NCT00500682
37. Weening JJ. Advancing nephrology around the globe: An invitation to contribute. J. Am. Soc. Nephrol. 2004 15 : 2761 2.